Seasoned investor and operator with a focus on growth-stage technology and healthcare companies, offering board and executive-level experience to institutional and venture investors. Linda Roitman has background in corporate finance, strategic M&A and portfolio company scaling, and frequently serves on boards or as an advisor to startups. Markets view her as a pragmatic capital allocator who supports revenue-driven growth and governance improvements.
Seasoned investor and operator with a focus on growth-stage technology and healthcare companies, offering board and executive-level experience to institutional and venture investors. Linda Roitman has background in corporate finance, strategic M&A and portfolio company scaling, and frequently serves on boards or as an advisor to startups. Markets view her as a pragmatic capital allocator who supports revenue-driven growth and governance improvements.
Prioritizes growth-stage technology and healthcare investments where board-level operational support accelerates revenue scaling. Focuses on capital-efficient rounds that de-risk through measurable commercial traction, repeatable go-to-market models and disciplined financial governance. Combines strategic M&A lens with hands-on portfolio work to drive exits over a three- to seven-year horizon, favoring companies with durable unit economics, strong leadership teams and clear paths to profitable scale.
Prioritizes growth-stage technology and healthcare investments where board-level operational support accelerates revenue scaling. Focuses on capital-efficient rounds that de-risk through measurable commercial traction, repeatable go-to-market models and disciplined financial governance. Combines strategic M&A lens with hands-on portfolio work to drive exits over a three- to seven-year horizon, favoring companies with durable unit economics, strong leadership teams and clear paths to profitable scale.
| Trades 54 | Longs Won 37/54 68% | Profit Factor 6.67 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $3.13M |
| Average Win $2.37M | Best Trade (Mar 31) $14.99M | Sharpe Ratio -12.54 |
| Average Loss -$775,028.19 | Worst Trade (Dec 30) -$5.44M | Z-Score 4.86 (100%) |
| Commissions $0 | Avg. Trade Length 8m 2d | Expectancy $1.38M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% |
| Consecutive Losing Trades | 386 | 347 | 309 | 270 | 231 | 193 | 154 | 116 | 77 | 39 |